mifepristone — United Healthcare
control of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome who have type 2 diabetes mellitus or glucose intolerance and who failed surgery or are not candidates for surgery
Initial criteria
- Diagnosis of endogenous Cushing’s syndrome (i.e., hypercortisolism is not a result of chronic administration of high dose glucocorticoids)
- AND one of the following: Diagnosis of type 2 diabetes mellitus OR Diagnosis of glucose intolerance
- AND one of the following: Patient has failed surgery OR Patient is not a candidate for surgery
Reauthorization criteria
- Documentation of a positive clinical response while on Korlym therapy
Approval duration
12 months